$1.71
3.39%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US4380831077
Symbol
QTTB

Homology Medicines, Inc. Stock price

$1.71
-0.41 19.34% 1M
-0.56 24.67% 6M
-1.73 50.29% YTD
-37.53 95.64% 1Y
-46.35 96.44% 3Y
-189.63 99.11% 5Y
-334.17 99.49% 10Y
-334.17 99.49% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.06 3.39%
ISIN
US4380831077
Symbol
QTTB
Industry

Key metrics

Basic
Market capitalization
$20.9m
Enterprise Value
$-21.2m
Net debt
positive
Cash
$54.8m
Shares outstanding
12.2m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.4
P/B
negative
Financial Health
Equity Ratio
6.2%
Return on Equity
-840.4%
ROCE
-
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-169.4m
EBIT
- | $-62.2m
Net Income
- | $-40.5m
Free Cash Flow
$-53.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -158.2%
EBIT
- | 5.9%
Net Income
- | 15.1%
Free Cash Flow
35.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-4.4
Short interest
10.4%
Employees
-
Rev per Employee
-
Show more

Is Homology Medicines, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Homology Medicines, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Homology Medicines, Inc. forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a Homology Medicines, Inc. forecast:

Buy
60%
Hold
40%

Financial data from Homology Medicines, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
35% 35%
-
- Research and Development Expense - -
-
-
-63 -63
21% 21%
-
- Depreciation and Amortization 0.49 0.49
4% 4%
-
EBIT (Operating Income) EBIT -63 -63
21% 21%
-
Net Profit -60 -60
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Homology Medicines, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Homology Medicines, Inc. Stock News

Neutral
PRNewsWire
5 days ago
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m.
Neutral
The Motley Fool
26 days ago
Q32 Bio (QTTB) Q2 Loss Drops 45%
Neutral
PRNewsWire
27 days ago
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- -- Cash and cash equivalents of $54.8 million as of...
More Homology Medicines, Inc. News

Company Profile

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Head office United States
CEO Jodie Morrison
Founded 2015
Website www.q32bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today